autologous fecal microbiota
Cell therapyexperimental
Clinical trial activity
16 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT03218579)
Timeline
Indications
Studied for
- Anti-Bacterial Agents · Phase 1
- Bipolar Disorder · Phase 2/Phase 3
- Diabetes Mellitus, Type 1 · Phase 2
- Diarrhea · Phase 2
- Digestive System Neoplasms · Phase 2
- Drug Resistance, Bacterial · Phase 2/Phase 3
- Graft vs Host Disease · Phase 1
- Irritable Bowel Syndrome · Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Scleroderma, Systemic · Phase 2
- Sprains and Strains · Phase 1
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous fecal microbiota
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07083882 | Phase 2 | Sep 30, 2025 | University of Amsterdam |
| NCT06609980 | Phase 1 | Aug 1, 2024 | Rutgers University |
| NCT05776914 | Phase 2 | Dec 31, 2023 | Mayo Clinic |
| NCT05430269 | N/A | Aug 1, 2022 | Charles University, Donatio Intensivistam Endowment Fund, Teaching Hospital Královské Vinohrady (FNKV) |
| NCT05323162 | N/A | Apr 30, 2022 | University of Amsterdam |
| NCT04745221 | Phase 1 | Mar 1, 2021 | Soochow University |
| NCT04300426 | Phase 2 | Apr 20, 2020 | South-Eastern Norway Regional Health Authority, University of Oslo |
| NCT04188743 | Phase 2/Phase 3 (Phase 3) | Dec 20, 2019 | Ghent University, Government of Belgium |
| NCT03808389 | N/A | Jan 30, 2019 | Ghent University, Government of Belgium, the Flanders Institute for Biotechnology, Vlaamse Parkinson Liga, Parkili |
| NCT03492502 | N/A | Nov 1, 2018 | Technion University |
| NCT03279224 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2018 | University of Toronto |
| NCT03110289 | N/A | Apr 30, 2017 | Government of Belgium, Katholieke Universiteit Leuven |
| NCT03061097 | Phase 1 | Apr 1, 2017 | Boston University, OpenBiome |
| NCT02928523 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | MaaT Pharma |
| NCT02046525 | Phase 2 | Mar 1, 2014 | Washington University in St. Louis |
| NCT03218579 | N/A | Feb 1, 2013 | Tel Aviv University, Weizmann Institute of Science |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Belgium | Government | 3 | 0 | 2 | 2017 |
| Ghent University | Academic/Hospital | 2 | 2 | 2 | 2019 |
| University of Amsterdam | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Boston University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Charles University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Donatio Intensivistam Endowment Fund | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2017 |
| MaaT Pharma | For profit | 1 | 1 | 1 | 2016 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2023 |
| OpenBiome | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Rutgers University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| South-Eastern Norway Regional Health Authority | Government | 1 | 0 | 1 | 2020 |
| Teaching Hospital Královské Vinohrady (FNKV) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Technion University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| the Flanders Institute for Biotechnology | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Oslo | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Vlaamse Parkinson Liga, Parkili | Academic/Hospital | 1 | 0 | 1 | 2019 |
22 organizations
Page 1 / 2